Cargando…
Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer
BACKGROUND: The most important prognostic factor in the ovarian cancer is optimal cytoreduction. The neoadjuvant chemotherapy, an only optional method of treatment in this case and is still the subject of debate. The object of this study was to evaluate the usefulness of markers: CA 125, HE4, YKL-40...
Autores principales: | Chudecka-Głaz, Anita Monika, Cymbaluk-Płoska, Aneta Alicja, Menkiszak, Janusz Leszek, Sompolska-Rzechuła, Agnieszka Monika, Tołoczko-Grabarek, Aleksandra Izabela, Rzepka-Górska, Izabella Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094548/ https://www.ncbi.nlm.nih.gov/pubmed/25018782 http://dx.doi.org/10.1186/1757-2215-7-62 |
Ejemplares similares
-
HE4 tumor marker concentration in neoplastic peritoneal effusion and in peritoneal fluid associated with benign gynecological diseases
por: Chudecka-Głaz, Anita, et al.
Publicado: (2014) -
Suitability assessment of baseline concentration of MMP3, TIMP3, HE4 and CA125 in the serum of patients with ovarian cancer
por: Cymbaluk-Płoska, Aneta, et al.
Publicado: (2018) -
Assessment of selected cytokines, proteins, and growth factors in the peritoneal fluid of patients with ovarian cancer and benign gynecological conditions
por: Chudecka-Głaz, Anita Monika, et al.
Publicado: (2015) -
Clinical importance of serum HE4 and MMP2 levels in endometrial cancer patients
por: Cymbaluk-Płoska, Aneta, et al.
Publicado: (2017) -
Risk Model in Women with Ovarian Cancer Without Mutations
por: Cymbaluk-Płoska, Aneta, et al.
Publicado: (2018)